New Rochelle, NY -- If the proven long-term benefits of smoking cessation are not enough to motivate young adults to stop smoking, a new study shows that 18- to 24-year olds who stop smoking for at least two weeks report substantially fewer respiratory symptoms, especially coughing. The study findings are detailed in Pediatric Allergy, Immunology, and Pulmonology, a peer-reviewed journal published by Mary Ann Liebert, Inc. The article is available online.
Karen Calabro, DrPH and Alexander Prokhorov, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, compared self-reported respiratory symptoms among two groups of college students who participated in programs designed to motivate them to stop smoking. One group achieved smoking cessation for two weeks or longer and the other group failed to stop smoking. More than half of the students smoked 5-10 cigarettes a day and had smoked for 1-5 years.
"That the benefit of stopping smoking starts in days to weeks-not years or decades-is important. Now health care providers can counsel young smokers that their breathing can feel better soon after they stop. This can help to motivate young adults to stop smoking before the severe damage is done," says Harold Farber, MD, MSPH, Editor of Pediatric Allergy, Immunology, and Pulmonology and Associate Professor of Pediatrics, Section of Pulmonology, Baylor College of Medicine, Houston, TX.
Pediatric Allergy, Immunology, and Pulmonology is a quarterly peer-reviewed journal published in print and online. The Journal synthesizes the pulmonary, allergy, and immunology communities in the advancement of the respiratory health of children. The Journal provides comprehensive coverage to further the understanding and optimize the treatment of some of the most common and costly chronic illnesses in children. It includes original translational, clinical, and epidemiologic research; public health, quality improvement, and case control studies; patient education research; and the latest research and standards of care for functional and genetic immune deficiencies and interstitial lung diseases. Tables of content and a free sample issue may be viewed online.
Mary Ann Liebert, Inc. is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Aerosol Medicine and Pulmonary Drug Delivery and Population Health Management. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available on our website.
Mary Ann Liebert, Inc.
140 Huguenot St.
New Rochelle, NY 10801-5215